Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
doi:10.1093/jnci/djj412
www } : CS1 maint: multiple names: authors list (link) Nature Biotechnology
The SELECT trial participants had pre-existing cardiovascular disease, which is an important population qualifier
Cartilage-specific targeting Why cartilage needs support: Cartilage has no blood supply (avascular) Nutrients diffuse slowly from synovial fluid Healing extremely slow (6-12+ months) Degenerates with age and use Poor regenerative capacity naturally Cartilage structure: Chondrocytes: Cartilage cells (only 1-5% of volume) Extracellular matrix: 95-99% of cartilage Collagen Type II (structure) Proteoglycans (water retention, cushioning) Water (65-80% of weight) Provides smooth, low-friction joint surface Absorbs compressive forces Age-related cartilage changes: Chondrocyte activity declines (less matrix production) Collagen degradation exceeds synthesis Water content decreases (less cushioning) Inflammatory markers increase Net result: Joint degeneration How Cartalax targets cartilage: Specific uptake by chondrocytes Gene regulation in cartilage cells Restores cartilage matrix balance Reduces age-related decline Conditions potentially helped: Osteoarthritis (cartilage wear) Age-related joint stiffness Post-injury cartilage damage Athletic overuse Preventive joint maintenance See best peptides for joint pain for comprehensive options
US$ 27.63
US$ 27.19
US$ 21.35
US$ 28.64
US$ 20.32
